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ABSTRACT  
Objectives: To evaluate candidate outcomes for disease-modifying trials in Huntington’s 
Disease (HD) over 6-, 9- and 15-month intervals, across multiple domains. To present 
guidelines on rapid efficacy readouts for disease-modifying trials. 
Methods: 40 controls and 61 HD patients, recruited from four EU sites, underwent 3T 
MRI and  standard clinical and cognitive assessments at  baseline,  6- and 15-months.  
Neuroimaging analysis included global and regional change in macrostructure (atrophy 
and cortical thinning) and microstructure (diffusion metrics).  The main outcome was 
longitudinal Effect Size (ES) for each outcome.  Such ES can be used to calculate sample-
size requirements for clinical trials for hypothesised treatment efficacies. 
Results:  Longitudinal  changes  in  macrostructural  neuroimaging  measures  such  as 
caudate atrophy and ventricular expansion were significantly larger in HD than controls, 
giving rise to consistently large ES over the 6-, 9- and 15-month intervals.  Analogous ES 
for  cortical  metrics  were  smaller  with  wide  confidence  intervals.    Microstructural 
(diffusion)  neuroimaging  metrics  ES  were  also  typically  smaller  over  the  shorter 
intervals,  although  caudate  diffusivity  metrics  performed  strongly  over  9-  and  15-
months.  Clinical and cognitive outcomes exhibited small longitudinal ESs, particularly 
over  6-  and  9-month  intervals,  with  wide  confidence  intervals,  indicating  a  lack  of 
precision.  
 
Conclusions: To exploit the potential power of specific neuroimaging measures such as Hobbs et al. p4 
 
 
caudate atrophy in disease-modifying trials, we propose their use as (1) initial short-
term readouts in early phase/proof-of-concept studies over six or nine months, and (2) 
secondary end-points in efficacy studies over longer periods such as 15 months.   
 
INTRODUCTION  
Major efforts are being invested in the development of disease-modifying therapies for 
neurodegenerative disorders such as Huntington’s disease (HD).[1] Testing their efficacy 
in clinical trials is a long and expensive process, with low success rates compared with 
other branches of medicine.[2] In HD, no phase III studies of putative disease-modifying 
treatments have been successful, despite many showing promise during early testing.
 
A wealth of observational data suggests that biomarkers of disease progression may 
facilitate the evaluation of disease-modifying therapies.[3-6] MRI-derived neuroimaging 
measures appear particularly powerful, with data suggesting that substantially fewer 
patients would be required to detect a reduction in rate of change in MRI biomarkers, 
compared  with  clinical  measures.[3-9]  However,  many  biomarkers  have  only  been 
evaluated over intervals ≥12 months.  
It may be advantageous for clinical trials to have efficacy readouts over short intervals 
such as six months, especially during the early phases, in order to provide confidence-
instilling data that the trial should progress to a larger scale. However, the use of short-
interval  biomarkers  in  clinical  trials  is  critically  dependent  on  their  validation  in 
longitudinal observational studies over the same time frame. Hobbs et al. p5 
 
 
Our objectives were to evaluate candidate outcomes for HD trials over 6-, 9- and 15-
month  intervals,  across  neuroimaging,  clinical  and  cognitive  domains.  Based  on  our 
findings,  we  present  guidelines  on  the  selection  of  outcomes  for  rapid  readouts  in 
clinical  trials.  It  is  hoped  these  data  will  directly  inform  the  design  of  HD  trials, 
facilitating the evaluation of treatments designed to slow the course of this devastating 
disease. 
METHODS 
Study Design 
This  was  a  longitudinal,  case-control  observational  study  in  HD.  Assessments  were 
performed at baseline, six and 15 months.  The study was approved by the local ethical 
committees.   
Participants 
Between March and October 2011, 40 controls and 61 HD patients were enrolled into 
Work Package 2 of the PADDINGTON study [10] at Leiden (Netherlands), London (UK), 
Paris  (France)  and  Ulm  (Germany).  Patients  were  recruited  from  research  centres. 
Controls were spouses, partners or gene-negative siblings in order to match patients to 
controls as closely as possible in terms of age, education level, background and home 
life. Patients were ideally required to be at stage I of the disease,[10] defined by a 
Unified Huntington’s Disease Rating Scale (UHDRS)[11] Total Functional Capacity (TFC) ≥ 
11, indicating good capacity in functional realms; however, five patients were granted 
waivers for not fulfilling this TFC criteria, as described in the Results. Inclusion criteria 
included  participants  being  18–65  years  of  age,  free  from  major  psychiatric  and Hobbs et al. p6 
 
 
concomitant neurological disorders, not currently participating in a clinical trial and able 
to tolerate and safely undergo MRI. Written informed consent was obtained from each 
subject.  
Procedures 
Clinical features were assessed using the UHDRS version ‘99. This included the Total 
Motor  Score  (TMS)  which  measures  a  range  of  motor  features  characteristically 
impaired in HD including gait, tongue protrusion, ocular function and postural stability; 
and the TFC scale which measures five components of daily living, including the capacity 
to work, manage finances and carry out domestic chores. The clinical examination was 
performed by raters certified by the European Huntington’s Disease Network (EHDN) 
UHDRS-TMS online certification (www.euro-hd.net).   
Cognitive features were assessed using the core EHDN cognitive battery, which consists 
of standard pencil and paper clinical neuropsychological tasks. All raters were trained on 
the  battery  and  all  tests  were  scripted.  Each  task  is  described  in  the  Supplemental 
Methods. 
MRI acquisition 
3T MRI (T1-, T2- and diffusion-weighted) were acquired based on protocols standardised 
for  multi-site  use.[6,10,12]  Scan  acquisition  protocols  have  been  described 
previously.[10] Quality control was performed on all datasets in pseudo-real time and 
rescans were requested where necessary. Data were pseudoanonymised and archived Hobbs et al. p7 
 
 
on a secure webportal. To avoid potential bias all image analysis was performed blinded 
to groupings.   
MRI: macrostructural (volumetric) analysis 
Pre-defined regions-of-interest (ROIs) for the volumetric analysis included the caudate, 
putamen,  white-matter,  grey-matter,  whole-brain,  lateral  ventricles  and  corpus 
callosum.  Cortical  thinning  was  also  examined  over  each  lobe  (parietal,  occipital, 
temporal and frontal). 
The  software  package  MIDAS[13]  was  used  to  delineate  the  whole-brain,  caudate, 
corpus  callosum  and  ventricles  at  baseline.[10]  Change  in  whole-brain,  caudate  and 
ventricular volume over the scanning interval was estimated using the Boundary Shift 
Integral (BSI) technique,[14] optimised for multi-site data,[15] within MIDAS software. 
The BSI is a semi-automated tool which measures volume change over time (atrophy) 
directly  from  within-subject  registered  scan  pairs.  Change  in  corpus  callosum  and 
putamen volume was estimated by delineating the structures at both time-points, either 
manually[11] (for all corpus callosum measurements) or with BRAINS3 software[6,16] 
(for all putamen measurements) and subtracting the volumes at each time-point. Grey-
matter  and  white-matter  volume  changes  were  computed  using  a  fluid-registration 
approach.[5,17,18] 
 
Cortical  thickness  measures  were  computed  using  FreeSurfer  software 
(http://surfer.nmr.mgh.harvard.edu/;  version  5.3.0).  All  scans  were  run  through  the 
longitudinal pipeline[19] and thickness estimates (mm) were extracted from each region 
defined by the Desikan-Killiany Atlas and averaged within lobes.[20] Hobbs et al. p8 
 
 
Full details of all volumetric image analysis are provided in the Supplemental Methods. 
MRI: microstructural (diffusion) analysis 
Diffusion metrics of fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity 
(AD) and radial diffusivity (RD) were generated over pre-defined ROIs (white-matter, 
corpus  callosum,  caudate  and  putamen)  for  all  three  visits  using  a  longitudinal 
registration pipeline. In brief, a common ROI mask was defined in a temporally unbiased 
‘mid-space’ based on within-subject registration of T1 images, before being non-linearly 
registered to each individual’s native FA images for each visit. The mean values were 
then  calculated  across  all  included  voxels  for  the  four  DTI  metrics.  This  analysis  is 
described in detail in the Supplemental Methods. 
All  segmentations  and  registrations  were  visually  inspected  for  accuracy  by  trained 
analysts, blinded to diagnosis. Excluded data-points are described in Supplemental End-
point Quality Control data. 
Statistical analysis 
Statistical analysis was performed by an independent team according to a predefined 
analysis plan. The repeated measures of each outcome variable were analysed using 
generalised  least  squares  regression  models,  with  variances  of  the  outcome  (and 
correlations between pairs of measures) allowed to differ both by group and by visit.  
The models included a group factor (HD or Control), calendar time from baseline (in 
days)  and  a  quadratic  term  to  allow  non-linear  change  over  the  three  visits  to  be 
modelled. The use of GLS models that jointly model all available outcomes provides Hobbs et al. p9 
 
 
some additional protection against the impact of missing values. Data only requires a 
“missing at random” assumption rather than the more restrictive “missing completely at 
random”  assumption  to  give  unbiased  estimates.[21]  Where  outcomes  directly 
measured  changes  (such  as  whole-brain  atrophy  between  two  visits)  the  outcome 
variables in the statistical models were change between baseline and six months (i.e. 6-
month interval), change between baseline and 15 months (i.e. 15-month interval) and 
change between six and 15 months (i.e. 9-month interval). Otherwise outcomes were 
measures made at baseline, six and 15 months. Linear and quadratic effects of time 
were included in all models with estimated between-group differences for the 6-, 9- and 
15-month  intervals  calculated  using  appropriate  linear  combinations  of  model 
parameters. All analyses adjusted for baseline age, gender and study site as well as 
interactions with the linear and quadratic effects of time. This was due to an a priori 
belief that age, gender and study site might affect slopes (and rates of change in slopes) 
as well as absolute levels of the outcomes. Models for non-imaging outcomes adjusted 
additionally  for  educational  level  (an  ordered  categorical  variable  treated  as  a 
continuous  covariate)  and  its  interactions  with  linear  and  quadratic  effects  of  time 
because  education  level  may  affect  performance  on  such  outcomes,  and  education 
levels were expected to differ systematically between HD and controls.  
Longitudinal Effect Sizes (ES) with 95% confidence intervals (CIs) for the difference in 
change over each interval were calculated as the covariate-adjusted difference in the 
mean of the change between HD participants and controls, divided by the estimated 
residual standard deviation (SD) of change in HD participants. Expression of results as Hobbs et al. p10 
 
 
(unit-free)  ES permits comparison  of changes measured  using  different metrics.  The 
square of ES is inversely related to sample-size requirements for clinical trials under the 
assumption that a 100% effective treatment will reduce the mean rate of change in HD 
cases to that in healthy controls without affecting the variability in these rates.[22] 95% 
CIs for the ES were calculated using bias corrected and accelerated (BCa) bootstrapping, 
with 2000 replications [23]. Here an ES of two implies that the mean change in HD is two 
SD away from that in controls. No formal criteria was used to assess “size” of ES. Since 
thresholds for such criteria could be argued to be arbitrary, the approach taken was to 
consider ES in relation to each other at each time point, and to evaluate whether the 
estimated  ES  and  95%  confidence  intervals  translated  into  feasible  sample  size 
estimates  for  the  specific  context  of  HD  clinical  trials.  No  adjustment  for  multiple 
comparisons  was  made  since  there  is  independent  scientific  interest  in  each  of  the 
variables.[24] Throughout, a cut-off of p=0.05 was used to establish formal statistical 
significance, with the actual p-values also considered in the interpretation of results. All 
analysis was performed in STATA v12. 
RESULTS 
Participants 
At baseline, five HD participants were granted waivers for being outside disease-stage 1; 
four were stage 2, one was stage 3.[10] All controls and 59/61 HD participants returned 
for the 6-month assessment; HD non-attendance was due to illness (n=2), both returned 
for the 15-month visit. 37/40 controls and 56/61 HD participants returned for the 15-
month assessment; HD drop-out was due to disease-related burden (n=1), inability to Hobbs et al. p11 
 
 
tolerate scanning (n=1), treatment for cancer (n=1) and psychiatric burden resulting in 
the site investigator withdrawing the participant (n=2).  Drop out in the control group 
was due to being the spouse of a withdrawn HD participant (n=1) or personal issues 
unrelated to the study (n=2).  
Table 1: Participant demographics at baseline  
Characteristic  Controls  (N=40)  HD Stage I  (N=61) 
Age (Years) 
Mean (SD) Min – Max 
51.4 (8.4)  29.0 – 66.6  48.7 (10.8)  23.5 – 7.3 
Gender 
       
Female N (%)  23  (57.5%)  37  (60.7%) 
Site 
       
Leiden N (%)  10  (25%)  17  (27.87%) 
London N (%)  10  (25%)  16  (26.23%) 
Paris N (%)  10  (25%)  13  (21.31%) 
Ulm N (%)  10  (25%)  15  (24.59%) 
TMS 
Mean (SD) Min - Max 
1.4 (1.9)  0-7  20.1 (10.7)  6-58 
TFC 
Mean (SD) Min - Max 
13.0 (0.2)  12-13  11.7 (1.5)  5-13 
CAG 
Mean (SD) Min - Max     
43.8 (3.2)  39 – 54 
Disease Burden Score * 
Mean (SD) Min - Max     
376.5 (85.2)  226.4  - 59.2 
TFC by site N(%) 
       
TFC 11-13 (HD Stage 1) 
   
56  (91.80%) Hobbs et al. p12 
 
 
TFC 7-10 (HD Stage 2) 
   
4
a  (6.56%) 
TFC 3-6 (HD Stage 3) 
   
1
b  (1.64%) 
All study participants attended for at least 1 follow up clinical visit  
SDMT = Symbol Digit Modality Test; TMS = Total Motor Score; TFC = Total Functional Capacity 
* Penny[25] Disease Burden Formula: Age x (CAG - 35.5) 
a 3 London, 1 Paris.
b  Paris 
 
Age and gender were well-balanced between groups (Table 1). Within the HD group, 
CAG,  disease  burden[25]  and  TFC  were  well-balanced  between  sites  (Supplemental 
Table 1). The average intervals in months (mean (SD)) between assessments in the HD 
group were 5.76 (1.36), 9.12 (0.99) and 14.88 (1.33). In the control group the intervals 
were 5.48 (1.08), 9.08 (0.88) and 14.50 (1.09). 
Effect sizes  
ES  for  the  difference  in  6-,  9-  and  15-month  change  between  HD  participants  and 
controls are presented in Table 2. Unadjusted baseline, 6- and 15-month findings for 
each outcome, with the number of data points for each variable, are presented by group 
in Supplemental Tables 3 and 4, with adjusted between-group differences in change 
over the 6-, 9-, and 15-month intervals. 
For clinical applicability, Table 2 should be viewed in conjunction with Figure 1, which 
depicts  the  relationship  between  ES  and  sample-size  requirements  for  disease-
modifying clinical trials (where the outcome is a single change measured between two 
time points) for varying assumed treatment efficacies. Hobbs et al. p13 
 
 
Table 2: 6-, 9- and 15-month Effect Size Estimates 
 
  Effect Size Estimate (95% CI) 
6-month interval  9-month interval   15-month interval 
Cognitive battery 
Letter Fluency   0.13 (-0.40, 0.60)  0.62 (-0.07, 1.18)  0.66 (-0.03, 1.32) 
Category Fluency   0.23 (-0.21, 0.66)  0.13 (-0.42, 0.66)  0.35 (-0.20, 0.89) 
HVLT delayed recall   0.49 (-0.01, 0.93)  0.00 (-0.53, 0.53)  0.50 (-0.12, 1.03) 
HVLT total correct   0.12 (-0.36, 0.59)  0.12 (-0.33, 0.61)  0.21 (-0.18, 0.58) 
HVLT Recognition   0.19 (-0.15, 0.45)  -0.26 (-0.69, 0.08)  -0.16 (-0.84, 0.32) 
SDMT  0.64 (0.08, 1.15)  0.34 (-0.11, 0.81)  0.80 (0.34, 1.25) 
Trail A Time (seconds)   0.21 (-0.10, 0.47)  -0.06 (-0.37, 0.31)  0.21 (-0.12, 0.57) 
Trail B Time (seconds)   0.11 (-0.27, 0.44)  -0.23 (-0.68, 0.16)  -0.07 (-0.49, 0.25) 
Stroop Word   0.29 (-0.09, 0.57)  0.06 (-0.26, 0.45)  0.31 (-0.08, 0.61) 
Stroop Colour   0.25 (-0.19, 0.68)  0.19 (-0.23, 0.59)  0.36 (-0.03 , 0.71) 
Stroop Interference   0.17 (-0.19, 0.54)  0.30 (-0.11, 0.69)  0.49 (-0.03 , 0.94) 
UHDRS clinical scales 
TMS (square root)   0.05 (-0.47, 0.61)  0.58 (0.09, 1.10)  0.55 (0.08, 1.12) 
TFC score   0.33 (-0.53, 1.33)  0.18 (-1.05, 1.32)  0.39 (-0.48, 1.24) 
Microstructural (diffusion) neuroimaging metrics 
Caudate FA   0.37 (-0.13, 0.83)  0.29 (-0.11, 0.65)  0.52 (0.12 , 0.88) 
Caudate MD (mm
2/s)   0.54 (0.20, 0.83)  0.62 (0.17, 1.03)  1.11 (0.77, 1.43) 
Caudate RD (mm
2/s)  0.52 (0.18, 0.82)  0.61 (0.18, 1.02)  1.07 (0.73 , 1.39) 
Caudate AD (mm
2/s)  0.56 (0.21, 0.86)  0.63 (0.15, 1.06)  1.174 (0.84, 1.49) 
Putamen FA   -0.04 (-0.36, 0.30)  -0.21 (-0.56, 0.15)  -0.27 (-0.65, 0.14) 
Putamen MD (mm
2/s)  0.43 (0.15, 0.72)  0.29 (-0.07, 0.64)  0.72 (0.38, 1.02) 
Putamen RD (mm
2/s)  0.33 (0.06, 0.60)  0.22 (-0.15, 0.56)  0.57 (0.23, 0.87) Hobbs et al. p14 
 
 
Putamen AD (mm
2/s)  0.55 (0.23, 0.85)  0.38 (0.03, 0.72)  0.92 (0.53, 1.26) 
White Matter FA   0.23 (-0.16, 0.64)  -0.09 (-0.48, 0.29)  0.17 (-0.28, 0.65) 
White Matter MD (mm
2/s)  0.50 (0.07, 0.93)  0.19 (-0.15, 0.54)  0.62 (0.20, 1.10) 
White Matter RD (mm
2/s)  0.39 (-0.05, 0.79)  0.10 (-0.21, 0.42)  0.51 (0.08, 0.94) 
White matter AD (mm
2/s)  0.50 (0.08, 0.89)  0.28 (-0.07, 0.81)  0.61 (0.21, 1.14) 
Corpus Callosum FA   0.43 (0.11, 0.82)  0.15 (-0.21, 0.47)  0.68 (0.17, 1.15) 
Corpus Callosum MD (mm
2/s)  0.25 (-0.18, 0.76)  0.15 (-0.30, 0.56)  0.30 (-0.12, 0.90) 
Corpus Callosum RD (mm
2/s)    0.37 (-0.00 , 0.88)  0.10 (-0.32, 0.50)  0.41 (-0.05, 1.03) 
Corpus Callosum AD (mm
2/s)  0.02 (-0.35, 0.38)  0.24 (-0.24, 0.64)  0.21 (-0.16, 0.72) 
Macrostructural (volumetric) neuroimaging metrics 
Caudate atrophy, CBSI (% baseline)   0.70 (0.36, 1.02)  0.64 (0.32, 0.98)  1.19 (0.74, 1.69) 
Whole-brain atrophy, BBSI (% baseline)   0.48 (0.16, 0.77)  0.70 (0.31, 1.06)  0.87 (0.47, 1.20) 
Ventricular  expansion, VBSI (mls)   0.79 (0.41, 1.14)  0.93 (0.55, 1.28)  1.03 (0.67, 1.32) 
Grey matter atrophy (% baseline)   0.77 (0.24, 1.23)  0.61 (0.30, 1.10)  0.86 (0.55, 1.22) 
White matter atrophy (% baseline)   0.62 (0.26, 1.03)  0.93 (0.57, 1.28)  0.96 (0.59, 1.33) 
Putamen atrophy (% baseline)   0.10 (-0.19, 0.40)  0.54 (0.20, 0.90)  0.78 (0.33, 1.18) 
Corpus callosal atrophy (% baseline)  0.11 (-0.27, 0.56)  0.17 (-0.21, 0.61)  0.21 (-0.19, 0.63) 
Macrostructural (cortical thinning) neuroimaging metrics 
Frontal lobe cortical thinning (mm)  -0.10 (-0.52, 0.29)  -0.06 (-0.51, 0.42)  -0.17 (-0.76, 0.41) 
Parietal lobe cortical thinning (mm)  0.04 (-0.32, 0.42)  0.25 (-0.15, 0.65)  0.38 (-0.11, 0.86) 
Temporal lobe cortical thinning (mm)  0.29 (-0.15, 0.75)  0.06 (-0.323, 0.51)  0.25 (-0.12, 0.70) 
Occipital lobe cortical thinning (mm)  0.30 (-0.16, 0.77)  0.22 (-0.20, 0.67)  0.51 (0.01, 1.00) 
ES estimates and 95% bias corrected and accelerated CIs over 6-, 9- and 15-month intervals for differences between 
change in HD and control participants. All analyses adjusted for age, gender and study site as well as interactions with 
the linear and quadratic effects of time. Models for non-imaging outcomes adjusted additionally for educational level 
and its interactions with linear and quadratic effects of time. Expression of results as ES permits comparison of changes 
measured using different metrics. Such ES (when squared) are inversely related to sample-size requirements for clinical 
trials under the assumption that a 100% effective treatment will reduce the mean rate of change in HD to that in 
healthy controls, without affecting the variability.  
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Macrostructural neuroimaging measures 
Longitudinal atrophy of the caudate, white-matter, grey-matter and whole-brain, and 
expansion of the lateral ventricles, produced relatively large ES over 6-, 9- and 15-month 
intervals (Table 2); with all between-group differences statistically significant (p<0.05, 
Supplemental  Table  4).  ES  for  these  metrics  were  relatively  consistent  in  that  they 
tended  to  change  in  magnitude  relative  to  the  interval  size.  Caudate  atrophy  and 
ventricular expansion performed particularly strongly over the 6-month interval.   
Putamen  atrophy  ES  were  small  and  not  statistically  significant  over  the  6-month 
interval (ES 0.101; 95% CI -0.187, 0.397) but performed more strongly over 9- and 15-
months, although  ES  were  smaller  than  for  the  caudate  and  the  other  more  global 
atrophy metrics listed above (Table 2).  
Corpus callosal atrophy was not significantly higher in patients than controls for all time 
intervals examined (Supplemental Table 3). 
Cortical thinning ES were small and between-group differences were only statistically 
significant for the occipital cortex over the 15-month interval (p=0.032, Supplemental 
Table 3); however this ES was relatively small with  a wide CI (0.512; 95% CI 0.011, 
0.997). 
Microstructural neuroimaging measures 
The microstructural (diffusion) metrics had typically smaller ES than the macrostructural 
atrophy  measurements,  although  the  caudate  diffusivity  metrics  performed  strongly Hobbs et al. p16 
 
 
(Table 2, Supplemental Table 3). In particular, caudate MD produced ES comparable to 
caudate atrophy over the 9- and 15-month intervals.  
FA ES were small and there was little evidence of statistically significant between-group 
differences  for  all  structures  examined  (caudate,  putamen,  global  white-matter  and 
corpus callosum), particularly over short intervals (Supplemental Table 3). 
Clinical measures 
The  standard  clinical  scales  examined  (TFC  and  TMS)  performed  relatively  poorly. 
Between-group differences in TFC were not statistically significant over 6-, 9- or 15-
month  intervals  (Supplemental  Table  3)  and  corresponding  ES  were  small,  with  CIs 
spanning  zero.  TMS  performed  more  strongly  than  TFC  over  the  9-  and  15-month 
intervals, with significant between-group differences and larger ES, although the CIs 
surrounding the ES estimates were wide (TMS over 15 months; ES 0.545 (95% CI: 0.075, 
1.123)). 
Cognitive measures 
Changes  in  the  majority  of  tasks  in  the  cognitive  battery  did  not  differ  significantly 
between HD and controls over all intervals examined (Table 2, Supplemental Table 3). 
The Symbol Digit Modality Task (SDMT) was the most promising non-imaging measure 
with an ES of 0.799 (95% CI: 0.344 to 1.254) over 15 months.  Hobbs et al. p17 
 
 
DISCUSSION 
Employing a multi-site study design with variable, short-interval observational periods, 
we report 6-, 9- and 15-month ES for a range of candidate biomarker outcomes for HD 
trials across multiple assessment modalities (macro- and micro-structural neuroimaging, 
clinical and cognitive). Reported ES can be used with a standard formula to calculate 
sample-size requirements for disease-modifying clinical trials[22] (Figure 1). This is the 
first time that ES have been reported over the short intervals of six and nine months. It 
is hoped that these data will be used to directly inform disease-modifying clinical trial 
design. 
Key Results 
Longitudinal  changes  in  macrostructural  neuroimaging  measures  such  as  caudate 
atrophy  and  ventricular  expansion  in  early  HD  subjects  were  larger  than  those  in 
controls giving rise to consistently large ES over the 6-, 9- and 15-month intervals, in 
agreement with previous multi-site observational findings over periods of 12-months 
and longer.[4,5,7] Analogous ES for cortical metrics were smaller, particularly over the 
shorter intervals. Although cortical thinning was recently used as an outcome measure 
in the PRECREST trial over a 6-month interval[26], our findings suggest it has limited 
longitudinal  sensitivity  and  would  require  substantially  larger  sample  sizes  than  the 
other macrostructural metrics reported here. Microstructural (diffusion) neuroimaging 
metrics  ES  were  also  typically  smaller  over  the  shorter  intervals,  although  caudate 
diffusivity metrics performed strongly over 9- and 15-months, in line with the most 
promising atrophy measures. To our knowledge, this is the first longitudinal multi-site Hobbs et al. p18 
 
 
study  to  examine  change  in  diffusion  metrics  in  HD.  Findings  are  encouraging, 
particularly within the striatal grey matter, in accordance with a recent report over 18 
months in a single-site study.[3]  
Clinical and cognitive outcomes exhibited small longitudinal ESs, particularly over 6- and 
9-month intervals, with wide confidence intervals, indicating a lack of precision. Of note, 
SDMT  appeared  particularly  promising  over  the  6-month  interval,  producing  ES 
comparable with caudate atrophy, although with noticeably wider confidence intervals. 
However, this result was not replicated over the 9-month interval, suggesting it to be a 
chance finding.  Over 15 months, SDMT performed strongly, producing ES comparable 
with putamen atrophy.  These longer-interval findings are in line with previous reports 
over 12- and 24-months, showing SDMT to be one of the most promising cognitive 
outcomes.[4,5,8,27]  
Interpretation: Clinical application 
To interpret findings within the context of designing disease-modifying clinical trials in 
HD,  we  must  consider  that  although  certain  neuroimaging  measures  appear  to  be 
particularly powerful, they would not be accepted as primary end-points in trials since 
they do not provide a direct measure of how the patient feels, functions or survives 
(www.fda.gov). Hence, to exploit the potential of these neuroimaging measures, we 
propose their  use  as:  (1)  initial  short-term  readouts  in  early  phase/proof-of-concept 
(PoC) studies over six or nine months; (2) interim or safety readouts over six or nine Hobbs et al. p19 
 
 
months in longer, larger efficacy studies (e.g. Phase III), and as; (3) secondary end-points 
in efficacy studies over longer periods such as 15 months.  
Short-term readouts  
Macrostructural  neuroimaging  measures  such  as  caudate  atrophy  and  ventricular 
expansion  may  be  able  provide  early  confidence-instilling  readouts  in  Phase  II  PoC 
studies over intervals such as 6- and 9- months, where the goal would be to assure 
safety  and  gather  initial  evidence  that  the  therapy  had  promising  properties. 
Encouraging  findings  from  such  readouts  would  facilitate  the  decision  whether  to 
further  invest  in  the  therapy,  increasing  participant  numbers  and  trial  duration.  An 
adaptive  approach  such  as  this  based  on  early,  meaningful  data  could  improve  the 
viability of disease-modifying clinical trials in HD.  
Interim read-outs and secondary end-points 
Once sufficiently powered, disease-modification could be demonstrated in large-scale 
Phase II/III efficacy studies of longer duration such as 15 months, using approved clinical 
measures such as TMS as the primary end-point, and specific neuroimaging metrics as 
secondary  end-points.  Supportive  data  from  a  strong  neuroimaging  biomarker 
programme would be important in demonstrating disease modification.  Hobbs et al. p20 
 
 
 
Figure 2 provides an example of how the ES data presented in Table 2 could be used to 
inform  clinical  trial  design.    Sample-size  requirements  are  presented  for  the  most 
promising outcomes from each assessment modality (Table 2), based on a treatment 
hypothesised to reduce the rate of change in each outcome by 50% (90% power and 5% 
significance level).  Based on these results, recommendations for selecting biomarkers 
for  short  PoC  studies  and  longer-term  Phase  III  trials  are  provided  as  “ticks”  (show 
potential),  “crosses”  (unlikely  to  be  suitable)  and  “question  marks”  (further  data  is 
required due to wide confidence intervals).  An important caveat of this figure is that 
sample sizes are heavily dependent on the magnitude of the hypothesised treatment 
effect (Figure 1).  For example, requirements would be four times larger if the effect was 
reduced to 25%.  Nevertheless, this approach does provide an estimate of sample-size 
requirements to sufficiently power trials, as well as a means of comparing the outcomes 
across assessment modalities. 
For example, in order to detect therapeutic effects on ventricular expansion following 
treatment periods of 6-, 9- or 15-months, sample-size requirements per treatment arm 
would  be  134  (95%  CI:  64,  495),  98  (95%  CI:  51,  275)  and  80  (95%  CI:  48,  186) 
respectively, for 50% efficacy.  Considering the magnitude of the sample sizes and the 
width of the confidence intervals, ventricular expansion may be a suitable biomarker for 
use in short-term PoC studies, as well as trials over a longer duration (Figure 2).   
Conversely,  to assess  the  effect  of  a therapy on  motor  progression, the commonly-
applied UHDRS-TMS may be suitable for use over 9- and 15-month intervals, given a Hobbs et al. p21 
 
 
50% treatment  effect; however,  the wide  confidence  intervals around  these  sample 
sizes indicate a lack of precision (Figure 2).   
Generalizability 
It is important to note that observational data should only be used to inform clinical 
trials involving similar cohorts and observational periods. The current study focussed 
predominately on stage 1 HD, the very early clinical phase of the disease, since disease-
modifying treatments are most likely to be efficacious in preserving function and quality 
of life when administered at this point. Therapies shown to be effective in these cohorts 
within an acceptable safety profile, may be administered during the premanifest stages 
of  the  disease,  prior  to  clinical  onset.  The  observational  PREDICT-HD  study,  which 
focuses on the premanifest stages of the disease, is ideally positioned to inform the 
design of such trials.[8]  
Limitations 
We must acknowledge the potential limitations of using neuroimaging biomarkers as 
efficacy readouts. It is possible that a positive macrostructural neuroimaging readout 
over  six  or  nine  months  may  not  be  indicative  of  longer-term  clinical  or  functional 
improvement.  Although associations between change in neuroimaging measures and 
functional decline have been reported in HD, causality is yet to be demonstrated.[4,7] 
Furthermore, these readouts may not be suitable for all types of intervention;  their 
utility may be dependent on the mechanism-of-action of the therapy, together with the 
time required for it to mediate an effect.  Nevertheless, these neuroimaging measures 
are  able  to  track  the  progression  of  pathological  atrophy  over  short  time  intervals, Hobbs et al. p22 
 
 
reproducible across multiple sites and objective.  They may provide valuable biomarkers 
in the assessment of disease-modifying compounds.  Another limitation includes the 
decision to focus on the corpus callosum as a whole, when there is evidence that each 
sub-region of the corpus callosum projects to distinct cortical regions and is likely to be 
differentially implicated in the disease process.  Future work should investigate these 
sub-structures independently, and whether the added complexity of delineating smaller 
with less well-defined regions is offset by a stronger atrophy signal. 
None of the participants in the current study were enrolled in clinical trials; however, 
many  were  on  medications  which  target  the  central  nervous  system  (CNS) 
(Supplemental Table 2). Mean dosages of CNS-targeting drugs were relatively low, with 
overlap in usage between groups. This study was not designed to examine the specific 
effects of medication on each outcome; however, we acknowledge medication usage as 
a potential confounder.  
Conclusion 
The  short-interval  observational  data  presented  here  are  complimentary  to  findings 
over  longer  intervals  in  others  such  as  the  TRACK-HD  and  the  PREDICT-HD  studies.  
Taken together, these studies can provide data to directly inform the design of clinical 
trials in HD, facilitating the evaluation of treatments designed to slow the course of this 
devastating disease.  Since HD is often regarded as a model neurodegenerative disease, 
amenable  to  early  intervention,[1]  research  into  this  disorder  may  inform  early-
intervention strategies for more prevalent neurodegenerative diseases.   
 Hobbs et al. p23 
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FIGURE LEGENDS 
Figure  1  Relationship  between  effect  sizes  and  sample-size  requirements  for 
randomised controlled trials where the outcome is a change measure between two 
time points.  Plots of this relationship are shown for treatments with efficacy levels of 
25% (red), 50% (blue) and 100% (green), assuming 90% power and a 5% significance 
level. 
Figure 2 Suggested biomarker selection for trials of a 50% effective disease-modifying 
agent Sample-size requirements are per treatment arm; calculated using the standard 
formula
22, with 90% power and two-tailed p<0.05, for therapies with 50% estimated 
treatment  efficacy.  Recommendations  are  given  as  ticks  ("show  potential"),  crosses 
("unlikely to be suitable") and question marks (“further data required – wide confidence 
intervals”). 
 
 
 
 
 
 
 
 
 
 Hobbs et al. p26 
 
 
REFERENCES 
1  Ross CA and Tabrizi SJ. Huntington's disease: from molecular pathogenesis to 
clinical treatment. Lancet Neurology 2011;10:83-98. 
2  Berger JR, Choi D, Kaminski HJ et al. Importance and Hurdles to Drug Discovery 
for Neurological Disease. Annals of Neurology 2013;74:441-446. 
3  Dominguez  JF,  Egan  GF,  Gray  MA  et  al.  Multi-Modal  Neuroimaging  in 
Premanifest and Early Huntington's Disease: 18 Month Longitudinal Data from 
the IMAGE-HD Study. Plos One 2013;8. 
4  Tabrizi SJ, Reilmann R, Roos RA et al. Potential endpoints for clinical trials in 
premanifest and early Huntington's disease in the TRACK-HD study: analysis of 
24 month observational data. Lancet Neurology 2012;11:42-53.  
5  Tabrizi SJ, Scahill RI, Durr A et al. Biological and clinical changes in premanifest 
and  early  stage  Huntington's  disease  in  the  TRACK-HD  study:  the  12-month 
longitudinal analysis. Lancet Neurology 2012;10:31-42. 
6  Tabrizi SJ, Langbehn DR, Leavitt BR et al. Biological and clinical manifestations of 
Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis 
of baseline data. Lancet Neurology 2009;8:791-801. 
7  Tabrizi SJ, Scahill RI, Owen G et al. Predictors of phenotypic progression and 
disease onset in premanifest and early-stage Huntington's disease in the TRACK-
HD  study:  analysis  of  36-month  observational  data.  Lancet  Neurology 
2013;12:637-649. 
8  Paulsen JS, Hayden M, Stout JC et al. Preparing for preventive clinical trials: the 
Predict-HD study. Arch. Neurol. 2006;63:883-890. 
9  Aylward EH, Nopoulos PC, Ross CA et al. Longitudinal change in regional brain 
volumes  in  prodromal  Huntington  disease.  J.  Neurol.  Neurosurg.  Psychiatry 
2011;82:405-410. 
10  Hobbs  NZ,  Cole  JH,  Farmer  RE  et  al.  Evaluation  of  multi-modal,  multi-site 
neuroimaging  measures  in  Huntington's  disease:  Baseline  results  from  the 
PADDINGTON study. Neuroimage: Clinical 2013;2:204-211. 
11  Huntington’s  Disease  Study  Group.  Unified  Huntington's  disease  rating  scale: 
Reliability and consistency. Movement Disorders 1996;11:136-142. 
12  Muller  HP,  Kassubek  J,  Gron  G  et  al.  Evaluating  multicenter  DTI  data  in 
Huntington's  disease  on  site  specific  effects:  An  ex  post  facto  approach. 
Neuroimage:Clinical 2013;2:161-167. Hobbs et al. p27 
 
 
13  Freeborough  PA,  Fox  NC  and  Kitney  RI.  Interactive  algorithms  for  the 
segmentation and quantitation of 3-D MRI brain scans. Computer Methods and 
Programs in Biomedicine 1997;53:15-25. 
14  Freeborough PA and Fox NC. The boundary shift integral: an accurate and robust 
measure of cerebral volume changes from registered repeat MRI.  IEEE Trans. 
Med. Imaging 1997;16:623-629. 
15  Leung KK, Clarkson MJ, Bartlett JW et al. Robust atrophy rate measurement in 
Alzheimer's  disease  using  multi-site  serial  MRI:  tissue-specific  intensity 
normalization and parameter selection. Neuroimage. 2010;50:516-523. 
16  Magnotta VA, Harris G, Andreasen NC, O’Leary DS, Yuh WT and Heckel D.  (2002) 
Structural  MR  image  processing  using  the  BRAINS2  toolbox.  Comput.  Med. 
Imaging Graph. 2002;26:251-264. 
17  Hobbs NZ, Henley SM, Ridgway GR. et al. The progression of regional atrophy in 
premanifest  and  early  Huntington's  disease:  a  longitudinal  voxel-based 
morphometry study. J Neurol. Neurosurg. Psychiatry 2010;81:756-763. 
18  Christensen  GE,  Rabbitt  RD  and  Miller  MI.  Deformable  templates  using  large 
deformation kinematics. IEEE Transactions on Image Processing 1996; 5:1435-
1447. 
19  Reuter  M,  Schmansky  NJ,  Rosas  HD  and  Fischl  B.  Within-subject  template 
estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402-
1418. 
20  Desikan  RS,  Segonne  F,  Fischl  B  et  al.  An  automated  labeling  system  for 
subdividing the human cerebral cortex on MRI scans into gyral based regions of 
interest. Neuroimage 2006;31:968-980. 
21  Rubin DB. Interference and missing data. Biometrika 1976; 63:581-592.   
22  Julious SA. Sample sizes in clinical trials, Boca Raton: Chapman and Hall; 2009. 
23  Carpenter J and Bithell J. Bootstrap confidence intervals: when, which, what? A 
practical guide for medical statisticians. Stat. Med. 2000;19:1141-1164. 
24  Rothman  KJ.  No  adjustments  are  needed  for  Multiple  Comparisons. 
Epidemiology 1990;1:43-46. 
25  Penney JB, Vonsattel JP, MacDonald ME, Gusella JF and Myers RH. CAG repeat 
number  governs  the  development  rate  of  pathology  in  Huntington's  disease. 
Annals of Neurology 1997;41:689-692. Hobbs et al. p28 
 
 
26  Rosas  HD,  Doros  G,  Gevorkian  S  et  al.  PRECREST:  A  phase  II  prevention  and 
biomarker trial of creatine in at-risk Huntington's Disease. Neurology 2014;82:1-
8. 
27  Stout  JC,  Jones  R,  Labuschagne  I  et  al.  Evaluation  of  longitudinal  12  and  24 
month  cognitive  outcomes  in  premanifest  and  early  Huntington’s  disease.  J 
Neurol Neurosurg Psychiatry 2012;83:687-694.  
 